• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

快速检索引用检索图表检索高级检索

• 投稿 • 上一篇    下一篇

5-氨基酮戊酸光动力疗法联合甘露聚糖肽胶囊治疗面部难治性扁平疣疗效观察

吴波,程燕,刘雪莹   

  1. 成都市第二人民医院皮肤科 成都市皮肤病性病防治研究所,成都市第二人民医院皮肤科 成都市皮肤病性病防治研究所,成都市第二人民医院皮肤科 成都市皮肤病性病防治研究所
  • 收稿日期:2017-12-24 修回日期:2018-02-26 出版日期:2018-02-25

Clinical Observation of 5-Aminolevulinic Acid Photodynamic Therapy Combined with Mannatide Capsule on the Treatment of Facial Verruca Plana

Wu Bo,Cheng Yan and Liu Xueying   

  1. Department Dermatology,the Second People’s Hospital of Chengdu,Sichuan,Chengdu Institute of Department and STD Prevention,Department Dermatology,the Second People’s Hospital of Chengdu,Sichuan,Chengdu Institute of Department and STD Prevention,Department Dermatology,the Second People’s Hospital of Chengdu,Sichuan,Chengdu Institute of Department and STD Prevention
  • Received:2017-12-24 Revised:2018-02-26 Online:2018-02-25

摘要: 目的: 观察5-氨基酮戊酸(ALA)光动力疗法联合甘露聚糖肽胶囊治疗难治性颜面部扁平疣的临床疗效及安全性。方法:将150例患者随机分为光动力对照组、甘露聚糖肽胶囊对照组、光动力联合甘露聚糖肽胶囊组(联合组),分别观察各组的疗效。结果:光动力对照组、甘露聚糖肽胶囊对照组、联合组的有效率依次分别为64.0%、56.0%和86.0%,联合组疗效明显优于光动力对照组和甘露聚糖肽胶囊对照组,差异有统计学意义(P<0.05)。3组痊愈患者均随访3个月,复发率分别为25.0%、33.3%、15.8%,联合组复发率低于光动力组和甘露聚糖肽组(P<0.05)。3组患者中仅光动力组、联合组分别有4例和2例患者在光动力治疗后面部皮肤出现轻度红肿、灼痛感、瘙痒感,生理盐水冷湿敷处理后上述症状缓解,未见其他明显不良反应。结论:ALA光动力疗法联合甘露聚糖肽胶囊治疗难治性颜面部扁平疣能提高临床治愈率,降低复发率,临床疗效确切,安全易操作。

Abstract: Objective: To observe the efficacy and safety of 5-aminolevulinic acid photodynamic therapy(ALA-PDT) combined with mannatide capsule on the treatment of facial verruca plana. Methods: 150 patients were randomly divided into the ALA-PDT group, the mannatide capsule group and the ALA-PDT+mannatide capsule group, the efficacy of each group was observed respectively. Results: The effective rates of the ALA-PDT group, the mannatide capsule group and the ALA-PDT+mannatide capsule group were 64.0%, 56.0% and 86.0%, and the ALA-PDT+mannatide capsule group had better effective rate than the other two groups(P<0.05). After 3 months follow-ups, the recurrence rates of the ALA-PDT group,the mannatide capsule group and the ALA-PDT+mannatide capsule group were 25.0%, 33.3% and 15.8%. The recurrence rate of the ALA-PDT+mannatide capsule group was lower than that of the other two groups(P<0.05). Mild facial redness, burning and itching occurred in 6 patients after ALA-PDT and relieved by hydropathic compress with normal saline. None serious adverse reactions were observed. Conclusion: The ALA-PDT combined with mannatide capsule can improve the clinical healing rate and lower the recurrence rate of facial verruca plana. This therapeutic method is safe and effective.